𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

✍ Scribed by Susan E. Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W. Robey; Maria Turner; Erin R. Gardner; William D. Figg; Seth M. Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L. Piekarz

Book ID
108676555
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
489 KB
Volume
148
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of interferon-Ξ±-2a plus p
Phase II trial of interferon-Ξ±-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma
✍ Vanna Chiarion-Sileni; Antonio Bononi; Cleto Veller Fornasa; Mariella Soraru; Ma πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 85 KB

## Purpose: To evaluate the efficacy and side effects of psolaren with ultraviolet light a (puva) and interferon-alpha-2a (ifn-alpha-2a) in patients with mycosis fungoides (mf) and sΓ©zary syndrome (ss). ## Patients and methods: From may 1993 to january 1999, 63 symptomatic patients with all stage

Results of a Phase II trial of oral bexa
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma
✍ David J. Straus; Madeleine Duvic; Timothy Kuzel; Steven Horwitz; Marie-France De πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 73 KB

## Abstract ## BACKGROUND. Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T‐cell lymphoma (CTCL). Interferon alfa has also been used for many years as an effective treatment for this disease. The results in recent case reports of the combi